A large trans-ancestry genome-wide association study meta-analysis of primary aldosteronism (PA) uncovered 19 associated genomic loci — 13 previously unreported — and demonstrated that a meaningful portion of PA's cardiovascular risk operates independently of systolic blood pressure elevation, particularly for heart failure and ischemic stroke. The TARID/TCF21 locus showed preferential association with aldosterone-producing adenoma over bilateral adrenal hyperplasia, suggesting distinct genetic architectures between subtypes. A polygenic risk score for PA correlated with higher aldosterone, lower serum potassium, and elevated systolic BP in general population cohorts, implying subclinical autonomous aldosterone excess exists on a continuous genetic spectrum rather than as a discrete disease threshold.
This preprint, not yet peer-reviewed, carries significant implications for hypertension medicine. Clinically, PA is dramatically underdiagnosed despite affecting an estimated 5–10% of hypertensive patients. The finding that cardiovascular harm occurs through BP-independent mechanisms — likely direct mineralocorticoid receptor activation causing fibrosis, inflammation, and endothelial dysfunction — reframes PA as a systemic cardiometabolic condition, not merely a correctable blood pressure disorder. It strengthens the case for aldosterone-targeted therapies (mineralocorticoid receptor antagonists like finerenone or spironolactone) beyond simple pressure control. The population-level polygenic risk score data challenge the binary disease concept entirely. Limitations include reliance on GWAS associations, which are correlational, and variable phenotyping across contributing cohorts. If confirmed after peer review, this work is genuinely paradigm-shifting for how aldosterone excess is screened, stratified, and treated.
